progress compon guidanc appear conserv
valuat reflect extent turnaround maintain neutral
maintain neutral rate follow
result better aggreg continu make progress return
market growth rate quit market growth
benefit rosa cementless product cycl bolster
invest rosa capit sale forc special sale invest
 believ initi product cycl help drive growth in-lin
zbh defin wamgr impli growth call least
updat guidanc xfx although note
quarterli pace reflect bill day benefit tougher comp
revenu rebat rel expect knee dental
xfx respect drove result quarter off-set continu
challeng spine xfx believ remain focal point come
quarter leadership transit zbh price headwind remain peer
within knee believ abat extent rosa
cementless take hold like improv management commentari
suggest limit expans combin increas spend
forthcom ep growth may concern investor look believ
current valuat reflect benefit previous depress valuat improv
progress today result assum full benefit turnaround
subsequ quarter see limit upsid current level encourag
progress maintain neutral
rosa dynam across multipl sector management note rosa knee
remain limit launch system refin base surgeon feedback
minim system placement sinc approv although knee growth
benefit rosa sale work toward develop
train program enabl seamless transit use robot new
account goal increas implant share futur rosa account
said focu knee applic seem take away focu
spine launch delay
 sale forc special note plan break sale forc
special categori sportsm upper extrem lower
extrem etc seen strategi work compani
wright medic rate integra buy pt
buy payback clear quarter initi
invest may impact oper leverag
dental begin fill previou caviti management invest dental
progress ensu dental post quarterli xfx growth first time
sinc previou discuss revolv around sell dental busi
management appear energ segment abil add valu
valuat rate neutral risk discuss
idc btig estim compani document
million except per share amount
current midst turnaround new management helm qualiti remedi effort one
zbh manufactur facil progress revenu guidanc equat xfx view
achiev remedi effort manufactur facil may take longer anticip interact
fda continu requir intens focu qualiti improv delay product gain depress gross
margin hamper sale momentum due dynam multipl challeng could impact
time management expect two-year turnaround
full commerci launch rosa knee
launch rosa spine
lap qualiti remedi effort improv inventori level
base case scenario fall midpoint guidanc
estim revenu rise report basi compar guidanc call
 adjust ep come compar guidanc
call
upsid estim could come faster expect adopt
npi reinvigor sale forc follow suppli improv addit
upsid could seen rosa system gain rapid adopt allow
implant share gain purchas account
resurfac qualiti suppli issu worsen compani sale forc
moral shrink margin combat competitor disappoint launch
rosa could contribut wors expect result
zimmer biomet diversifi
medic technolog compani
design manufactur broad
rang orthopaed reconstruct
product zimmer hold
found justin
zimmer took current
form zimmer acquir
biomet inc april today
zimmer biomet oper global
countri
employe across world
zimmer biomet report result overal revenu came line btig expect
consensu expect call segment report revenu knee
hip dental spine cmf compar btig/consensu
estim constant
currenc revenu growth btig expect sequenti gross margin
adjust slightli btig estim inventori initi cost continu declin sg
percentag revenu came versu btig estim call revenu versu
btig estim told adjust ep quarter btig consensu estim
made follow chang model
within revenu mix increas expect growth beyond make progress toward
improv top-lin perform increas expect growth knee
respect within hip leav estim rel unchang previous model impact
collar stem introduct within increas expect growth outer
year make invest segment drive top-lin perform within dental increas
actualsbtig estimate variancetot net bpssg spend bpsr spend bpsadj ebit bpsadj ebitda bpstax bpssourc btig research estim compani filingsvari
growth expect within spine cmf lower
expect transit new leadership combin delay rosa spine limit
improv categori time leav categori unchang
 tweak gm expect close align management commentari suggest
improv leav forward gm expect larg unchang within oper expens
increas expens profil sg reflect zbh continu invest across varieti area
includ robot research sale forc expans special lower tax rate beyond
reflect zbh improv tax profil told estim increas modestli reflect improv busi
zimmer biomet rate neutral zimmer biomet trade estim next twelv month ep project
versu comp group forecast revenu compound-annual-growth-rate
comp group forecast ep compound-annual-growth-rate also comp group feel
discount overal comp group warrant given zimmer biomet current top-lin growth expect addit
invest oper expens beyond btig publish price target neutral rate stock
risk rate includ follow upsid perspect shorter organiz turnaround assum
less regulatori challeng assum faster resolut on-go qualiti remedi lack gm pressur strong
uptak robot downsid perspect loss market share addit regulatori requir
cost limit robot adopt longer expect improv compani cultur
btig research estim compani filingsnewold chang
incom etot y/i sale special oper incom incom tax expens net share net incom share gross net net oper tax expens btig research estim compani report
revenu y/i btig research estim compani report
btig cover compani mention report
appendix analyst certif import disclosur
